High-intensity focused ultrasound therapy as part of combined treatment for inoperable pancreatic cancer

Khitrova A.N.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

SPIN RSCI: 2787-5414
Scopus AuthorID: 6603382243
ResearcherID: U-5441-2019
ORCID: 0000-0003-4879-2687

Kornietskaia A.L.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Moskvicheva L.I.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

High-intensity focused ultrasound therapy as part of combined treatment for inoperable pancreatic cancer

Authors:

Khitrova A.N., Bolotina L.V., Kornietskaia A.L., Moskvicheva L.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2020;9(1): 50‑54

DOI: 10.17116/onkolog2020901150

Downloaded: 55

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Khitrova AN, Bolotina LV, Kornietskaia AL, Moskvicheva LI. High-intensity focused ultrasound therapy as part of combined treatment for inoperable pancreatic cancer. P.A. Herzen Journal of Oncology. 2020;9(1):50‑54. (In Russ.)
https://doi.org/10.17116/onkolog2020901150

Close metadata

Recommended articles:

Colorectal cancer and gut microbiota. P.A. Herzen Journal of Oncology. 2024;(2):60-66

Uncontrolled inhibition of checkpoints. P.A. Herzen Journal of Oncology. 2024;(2):67-73

Correction of anemia and mitochondrial dysfunction by iron citrate «Sintezit» during neoadjuvant chemotherapy for colorectal cancer and lymphoproliferative disorders. Russian Journal of Evidence-Based Gastroenterology. 2024;(1):21-31

Gonadotropin-releasing hormone agonists as a chance for motherhood in the future. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):30-36

The Russian consensus on the treatment of intrahepatic cholangiocarcinoma. Pirogov Russian Journal of Surgery. 2024;(10):7-20

Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in antitumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143

In connection with the active development of science and technology in the past 10 years, new methods have been introduced into practical medicine to control a number of diseases and conditions. The use of new therapeutic techniques is of particular importance in oncology, which is associated with the severity of the course of tumor pathology in patients and with the particular difficulty in choosing treatments. Pancreatic cancer is today one of the most unfavorable tumors that are characterized by a high risk for tumor complications, a significant general health deterioration and a decrease in patient performance, and the high rate of untimely diagnosis and the low rates of survival in the patients. Due to the significant prevalence of the disease at the verification stage, a significant proportion of patients with this diagnosis cannot receive radical surgical treatment. Chemotherapy is the mainstay of specific treatment in these cases. High-intensity focused ultrasound therapy is one of the local therapy techniques used to enhance the efficiency of specific drug treatment in patients with locally advanced and generalized pancreatic cancer. The efficiency and safety of local treatment in combination with chemotherapy in this category of patients may suggest that it is advisable to perform this type of combined for the unoperated because of the existing somatic disorders in patients with localized pancreatic cancer. The described case suggests that high-intensity focused ultrasound therapy in combination with chemotherapy is justified in the unoperated patients with somatic disorders in the presence of pancreatic cancer.

Keywords:

unresectable pancreatic cancer

unoperated patient

high-intensity focused ultrasound therapy

HIFU therapy

non-invasive ultrasound ablation

chemotherapy

Authors:

Khitrova A.N.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

SPIN RSCI: 2787-5414
Scopus AuthorID: 6603382243
ResearcherID: U-5441-2019
ORCID: 0000-0003-4879-2687

Kornietskaia A.L.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Moskvicheva L.I.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

List of references:

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(1):69-90. https://doi.org/10.3322/caac.20107
Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009;6(12):699-708. https://doi.org/10.1038/nrgastro.2009.177
Yamagishi Y, Higuchi H, Izumiya M, Sakai G, Iizuka H, Nakamura S, Adachi M, Hozawa S, Takaishi H, Hibi T. Gemcitbine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol. 2010;45(11):1146-1154. https://doi.org/10.1007/s00535-010-0258-9
Hanada K, Hino F, Amano H, Fukuda T, Kuroda Y. Current treatment strategies for pancreatic cancer in the elderly. Drugs Aging. 2006;23(5):403-410. https://doi.org/10.2165/00002512-200623050-00004
Marechal R., Demols A, Gay F, de Maertelaer V, Arvanitaki M, Hendlisz A, Van Laethem JL. Tolerance and efficacy of gemcitabine and gemcitabine-baced regimens in elderly patients with advanced pancreatic cancer. Pancreas. 2008;36(3):16-21. https://doi.org/10.1097/mpa.0b013e31815f3920
Hentic O, Dreyer C, Rebours V, Zappa M, Lévy P, Raymond E, Ruszniewski P, Hammel P. Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol. 2011;17(30):3497-3502. https://doi.org/10.3748/wjg.v17.i30.3497
Kuroda T, Kumagi T, Yokota T, Azemoto N, Hasebe A, Seike H, Nishiyama M, Inada N, Shibata N, et al. Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. BMC Gastroenterology. 2017;17(1):66. https://doi.org/10.1186/s12876-017-0623-8
Bjerregaard JK, Mortensen MB, Schønnemann KR, Pfeiffer P. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer. 2013;49(1):98-105. https://doi.org/10.1016/j.ejca.2012.07.017
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966. https://doi.org/10.1200/JCO.2006.07.9525
Trouilloud I, Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T, Aparicio T, Thirot-Bidault A, Lobry C, Asnacios A, et al. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). Eur J Cancer. 2014;50(18):3116-3124. https://doi.org/10.1016/j.ejca.2014.09.015
Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol. 2016;22(31):6987-7005. https://doi.org/10.3748/wjg.v22.i31.6987
Keane MG, Bramis K, Pereira SP, Fusai GK. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol. 2014;20(9):2267-2278. https://doi.org/10.3748/wjg.v20.i9.2267
Gao HF, Wang K, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Wang P, Shi WD, Sheng YH. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Hepatogastroenterology. 2013;60(128):1906-1910. https://doi.org/10.1155/2014/205325
Zhang L, Wang ZB. High-intensity focused ultrasound tumor ablation: review of ten years of clinical experience. Front Med China. 2010;4:294-302. https://doi.org/10.1007/s11684-010-0092-8
Sofuni A, Moriyasu F, Sano T, Yamada K, Itokawa F, Tsuchiya T, Tsuji S, Kurihara T, Ishii K, Itoi T. The current potential of high-intensity focused ultrasound for pancreatic carcinoma. J Hepatobiliary Pancreat Sci. 2011;18(3):295-303. https://doi.org/10.1007/s00534-010-0355-4
Seufferlein T, Porzner M, Heinemann V, Tannapfel A, Stuschke M, Uhl W. Ductal pancreatic adenocarcinoma. Deutsch Arztebl Int. 2014;111(22):396-402. https://doi.org/10.3238/arztebl.2014.0396
Suleimanov EA, Filonenko EV, Moskvicheva LI, Kaprin AD, Kostin AA, Samsonov YuV, Isaev AR. The possibility of HIFU therapy at the present stage. Issledovaniya i praktika v meditsine (Research and Practical Medicine Journal). 2016;3(3):76-82. (In Russ.) https://doi.org/10.17709/2409-2231-2016-3-3-8
Marinova M, Huxold HC, Henseler J, Mücke M, Conrad R, Rolke R, Ahmadzadehfar H, Rauch M, Fimmers R, Luechters G, et al. Clinical effectiveness and potential survival benefit of US-guided high-intensity focused ultrasound therapy in patients with advanced-stage pancreatic cancer. Ultraschall Med. 2019;40(5):625-637. https://doi.org/10.1055/a-0591-3386
Zhou D, Lv W, Yan T, Wang G, Zhao W, Zhang T. High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma. Ther Clin Risk Manag. 2016;12:687-691. https://doi.org/10.2147/tcrm.s90567
Moskvicheva LI, Petrov LO, Sidorov DV. The possibilities of modern methods of ablation in non-resectable locally advanced pancreatic cancer. Issledovaniya i praktika v meditsine (Research and Practical Medicine Journal). 2018;5(2):86-99. (In Russ.) https://doi.org/10.17709/2409-2231-2018-5-2-10

Close metadata